Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sven Korte is active.

Publication


Featured researches published by Sven Korte.


Journal of Medical Primatology | 2009

High Definition Oscillometry: a novel technique for non-invasive blood pressure monitoring in the cynomolgus monkey (Macaca fascicularis)

Barthel Schmelting; Marc Niehoff; B. Egner; Sven Korte; Gerhard F. Weinbauer

Background  Current approaches for accurate blood pressure determination rely predominantly on invasive techniques. High Definition Oscillometry (HDO) was evaluated as a potential non‐invasive approach for accurate blood pressure recordings in cynomolgus monkeys.


Journal of Applied Toxicology | 2014

Differential responses to JNJ‐37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague–Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics

Eric J. de Waal; Maria Desmidt; Sven Korte; Marc Niehoff; Kevan Chase; Wayne Arrowsmith; Ann Lampo

JNJ‐37822681 is a potent, specific and fast dissociating dopamine D2 receptor antagonist intended for the treatment of schizophrenia. Its nonclinical toxicological profile was investigated in a series of general repeat dose toxicity studies in cynomolgus monkeys and Sprague–Dawley rats. The maximum duration of treatment was 9 and 6 months, respectively. Interspecies differences were noted in the response to JNJ‐37822681 in terms of extrapyramidal (EPS)‐like clinical signs and prolactin‐mediated tissue changes in the mammary gland. Monkeys showed severe EPS‐like clinical signs such as abnormal posture, abnormal eye movements and hallucination‐like behavior at relatively low exposures compared to those associated with EPS in patients with schizophrenia. The high sensitivity of the monkey to JNJ‐37822681‐induced EPS‐like signs was unexpected based on the fast dissociating properties of the compound. Rats, however, were not prone to EPS. Elevated serum prolactin levels were found in rats and monkeys. While rats showed slight to moderate prolactin‐related tissue changes upon histopathological examination in all studies, which among others affected the mammary gland, only minor mammary gland tissue changes were noted in monkeys. Prolactin levels were only slightly increased in patients with schizophrenia receiving relatively high dose levels of JNJ‐37822681. The monkey toxicology studies did not provide an exposure‐based safety margin, while in rats adverse effects were only noted at exposures considerably higher than those achieved at efficacious plasma concentrations in the clinic. Overall, the available data suggest that the cynomolgus monkey showed better predictivity towards the nature of JNJ‐37822681‐associated adverse events in humans than the Sprague–Dawley rat. Copyright


The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment | 2015

Basic Physiology of Callithrix jacchus

Kerstin Mätz-Rensing; Sven Korte

The common marmoset, a unique South American New World monkey species, is widespread in laboratory settings and in zoological gardens. In recent years, common marmosets have become a suitable animal model in many research fields. Their small size, easy handling and husbandry, early sexual maturity, and short gestation makes them attractive for toxicology and reproductive biology. Important distinctions from other primate species regarding nutrition, reproduction, and development exist, and this knowledge is essential for successful husbandry breeding and study design. This chapter provides an overview of important aspects of the basic physiology of the common marmoset.


The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment | 2015

Considering the Use of Callithrix jacchus

C. Marc Luetjens; J. Kaspareit; Sven Korte; Joachim Wistuba

Abstract In this chapter we review the data available on the use of marmosets as a valuable NHP model and report on histopathological specificities in a variety of organs. Based on the differences described, the marmoset model is discussed in the context of toxicological safety assessments as well as a model for general research on the pathophysiology of human diseases.


Journal of Pharmacological and Toxicological Methods | 2007

MODIFIED IRWIN TEST AS DIAGNOSTIC TOOL TO MONITOR NEUROBEHAVIOURAL CHANGES IN MONKEYS

Sven Korte; Antje Fuchs; Gerhard F. Weinbauer; Elena Moscardo; Alessandra Giarola


Toxicological Sciences | 2016

Safety Evaluation of CNS Administered Biologics—Study Design, Data Interpretation, and Translation to the Clinic

Brian R. Vuillemenot; Sven Korte; Teresa Leah Wright; Eric L. Adams; Robert B. Boyd; Mark Butt


Journal of Pharmacological and Toxicological Methods | 2018

Considerations on the neurobehavioral assessment (modified Irwin test) in non-human primates

Daniela Smieja; Marc Niehoff; Sven Korte


The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment | 2015

Study Design Considerations, Technical Procedural Aspects, Scheduling, and Dosing Sampling Volumes

Werner Frings; Marc Niehoff; Sven Korte


The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment | 2015

Chapter 35 – Gaps and Future Challenges

Joerg Bluemel; Sven Korte; Emanuel Schenck; Gerhard F. Weinbauer


Archive | 2015

Gaps and Future Challenges

Joerg Bluemel; Sven Korte; Emanuel Schenck; Gerhard F. Weinbauer

Collaboration


Dive into the Sven Korte's collaboration.

Researchain Logo
Decentralizing Knowledge